Analyst Expects ‘Somewhat Smaller Effect Size’ From Gossamer Bio’s Upcoming PAH Trial
Raymond James maintains Outperform on Gossamer Bio Inc (NASDAQ:GOSS) with a price target down from $18 to $15. The analyst expects a…
What 4 Analyst Ratings Have To Say About Gossamer Bio
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter: Bullish Somewhat Bullish Indifferent…
What 4 Analyst Ratings Have To Say About Gossamer Bio
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings:
Wedbush Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $24
Wedbush analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $24.
Barclays Maintains Overweight on Gossamer Bio, Raises Price Target to $18
Barclays analyst Carter Gould maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and raises the price target from $12 to $18.
Raymond James Maintains Outperform on Gossamer Bio, Raises Price Target to $18
Raymond James analyst Steven Seedhouse maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and raises the price target from $14 to $18.
Gossamer Bio: Q2 Earnings Insights
Gossamer Bio (NASDAQ:GOSS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Gossamer Bio Q2 EPS $(0.74) Up From $(0.80) YoY
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.74) per share. This is a 7.5 percent increase over losses of $(0.80) per share from the same period last year.
